PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
7.01%
Some net income increase while CRVO is negative at -6.43%. John Neff would see a short-term edge over the struggling competitor.
8.54%
D&A growth of 8.54% while CRVO is zero at 0.00%. Bruce Berkowitz would see a mild cost difference that must be justified by expansions.
100.00%
Deferred tax of 100.00% while CRVO is zero at 0.00%. Bruce Berkowitz would see a partial difference that can matter for future cash flow if large in magnitude.
48.65%
SBC growth well above CRVO's 32.27%. Michael Burry would flag major dilution risk vs. competitor’s approach.
-142.09%
Negative yoy working capital usage while CRVO is 355.83%. Joel Greenblatt would see more free cash if revenue remains unaffected, giving a short-term advantage.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-124.49%
Both negative yoy AP, with CRVO at -226.25%. Martin Whitman would find an overall trend toward paying down supplier credit in the niche.
-84.29%
Both reduce yoy usage, with CRVO at -52.17%. Martin Whitman would suspect an industry or cyclical factor pulling back on these items.
47.93%
Some yoy increase while CRVO is negative at -2564.00%. John Neff would see competitor possibly reining in intangible charges or revaluations more effectively than we do.
1.55%
Operating cash flow growth below 50% of CRVO's 43.92%. Michael Burry would see a serious shortfall in day-to-day cash profitability.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
We cut debt repayment yoy while CRVO is 0.00%. Joel Greenblatt sees competitor possibly lowering risk more if expansions do not hamper them.
1131.77%
Issuance growth of 1131.77% while CRVO is zero at 0.00%. Bruce Berkowitz sees a mild dilution that must be justified by expansions or acquisitions vs. competitor’s stable share base.
No Data
No Data available this quarter, please select a different quarter.